270 related articles for article (PubMed ID: 22710719)
1. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
Gómez-Casares MT; García-Alegria E; López-Jorge CE; Ferrándiz N; Blanco R; Alvarez S; Vaqué JP; Bretones G; Caraballo JM; Sánchez-Bailón P; Delgado MD; Martín-Perez J; Cigudosa JC; León J
Oncogene; 2013 Apr; 32(17):2239-46. PubMed ID: 22710719
[TBL] [Abstract][Full Text] [Related]
2. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
[TBL] [Abstract][Full Text] [Related]
3. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
Albajar M; Gómez-Casares MT; Llorca J; Mauleon I; Vaqué JP; Acosta JC; Bermúdez A; Donato N; Delgado MD; León J
Mol Cancer Res; 2011 May; 9(5):564-76. PubMed ID: 21460180
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
7. Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest.
Acosta JC; Ferrándiz N; Bretones G; Torrano V; Blanco R; Richard C; O'Connell B; Sedivy J; Delgado MD; León J
Mol Cell Biol; 2008 Dec; 28(24):7286-95. PubMed ID: 18838534
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N
Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706
[TBL] [Abstract][Full Text] [Related]
9. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
[TBL] [Abstract][Full Text] [Related]
11. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
13. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
Lupino E; Ramondetti C; Buccinnà B; Piccinini M
Biochem Pharmacol; 2014 Nov; 92(2):235-50. PubMed ID: 25264277
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
[TBL] [Abstract][Full Text] [Related]
17. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
[TBL] [Abstract][Full Text] [Related]
18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
19. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
20. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
